Citadel Advisors’s Medpace MEDP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.98M | Buy |
18,700
+3,900
| +26% | +$2M | ﹤0.01% | 3402 |
|
|
2025
Q4 | $8.31M | Sell |
14,800
-7,900
| -35% | -$4.48M | ﹤0.01% | 3494 |
|
|
2025
Q3 | $11.7M | Buy |
22,700
+3,000
| +15% | +$1.31M | ﹤0.01% | 3041 |
|
|
2025
Q2 | $6.18M | Sell |
19,700
-13,400
| -40% | -$4.02M | ﹤0.01% | 3759 |
|
|
2025
Q1 | $10.1M | Buy |
33,100
+4,500
| +16% | +$1.51M | ﹤0.01% | 2847 |
|
|
2024
Q4 | $9.5M | Buy |
28,600
+7,500
| +36% | +$2.54M | ﹤0.01% | 3053 |
|
|
2024
Q3 | $7.04M | Buy |
21,100
+4,800
| +29% | +$1.82M | ﹤0.01% | 3422 |
|
|
2024
Q2 | $6.71M | Sell |
16,300
-46,900
| -74% | -$18.6M | ﹤0.01% | 3313 |
|
|
2024
Q1 | $25.5M | Buy |
63,200
+49,300
| +355% | +$17.3M | ﹤0.01% | 1832 |
|
|
2023
Q4 | $4.26M | Sell |
13,900
-6,700
| -33% | -$1.81M | ﹤0.01% | 4041 |
|
|
2023
Q3 | $4.99M | Buy |
20,600
+17,000
| +472% | +$4.35M | ﹤0.01% | 3643 |
|
|
2023
Q2 | $865K | Buy |
3,600
+400
| +13% | +$83.1K | ﹤0.01% | 6759 |
|
|
2023
Q1 | $602K | Sell |
3,200
-26,200
| -89% | -$5.42M | ﹤0.01% | 7936 |
|
|
2022
Q4 | $6.24M | Buy |
29,400
+18,700
| +175% | +$3.74M | ﹤0.01% | 3509 |
|
|
2022
Q3 | $1.68M | Sell |
10,700
-3,300
| -24% | -$527K | ﹤0.01% | 5924 |
|
|
2022
Q2 | $2.1M | Buy |
14,000
+5,900
| +73% | +$854K | ﹤0.01% | 5450 |
|
|
2022
Q1 | $1.32M | Sell |
8,100
-300
| -4% | -$49.5K | ﹤0.01% | 7042 |
|
|
2021
Q4 | $1.83M | Buy |
8,400
+800
| +11% | +$168K | ﹤0.01% | 6457 |
|
|
2021
Q3 | $1.44M | Sell |
7,600
-15,200
| -67% | -$2.77M | ﹤0.01% | 7185 |
|
|
2021
Q2 | $4.03M | Buy |
22,800
+17,900
| +365% | +$3.09M | ﹤0.01% | 4921 |
|
|
2021
Q1 | $804K | Sell |
4,900
-5,000
| -51% | -$765K | ﹤0.01% | 8631 |
|
|
2020
Q4 | $1.38M | Buy |
9,900
+4,400
| +80% | +$555K | ﹤0.01% | 6110 |
|
|
2020
Q3 | $615K | Sell |
5,500
-9,100
| -62% | -$1.05M | ﹤0.01% | 6919 |
|
|
2020
Q2 | $1.36M | Buy |
14,600
+700
| +5% | +$59.6K | ﹤0.01% | 5266 |
|
|
2020
Q1 | $1.02M | Buy |
13,900
+2,500
| +22% | +$217K | ﹤0.01% | 5302 |
|
|
2019
Q4 | $958K | Buy |
11,400
+3,600
| +46% | +$279K | ﹤0.01% | 5658 |
|
|
2019
Q3 | $656K | Sell |
7,800
-5,000
| -39% | -$378K | ﹤0.01% | 6287 |
|
|
2019
Q2 | $837K | Sell |
12,800
-20,600
| -62% | -$1.19M | ﹤0.01% | 5987 |
|
|
2019
Q1 | $1.97M | Buy |
33,400
+13,700
| +70% | +$818K | ﹤0.01% | 4496 |
|
|
2018
Q4 | $1.04M | Buy |
19,700
+2,000
| +11% | +$110K | ﹤0.01% | 5236 |
|
|
2018
Q3 | $1.06M | Buy |
+17,700
| New | +$968K | ﹤0.01% | 5438 |
|
Other funds holding MEDP
VPM
VCM
WA
Citadel Advisors's MEDP Position: Q1 2026 in Review
Citadel Advisors reduced its Medpace (MEDP) stake by 99% in Q1 2026, selling an estimated $30.2M and leaving 808 shares worth $388K. The position accounts for ﹤0.01% of the portfolio, ranked #9877.
Citadel Advisors first reported a position in MEDP in Q3 2016 and has held it in 34 quarters since. The position peaked at $37.7M in Q1 2024. 729 funds tracked by Wall St. Rank hold MEDP as of Q1 2026.
- Citadel Advisors held 808 shares of Medpace worth $388K as of Q1 2026.
- Citadel Advisors sold 58,932 Medpace shares in Q1 2026, an estimated $30.2M.
- Medpace made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9877 holding.
- Citadel Advisors first reported a position in Medpace in Q3 2016 and has held it in 34 quarters since.
- Citadel Advisors's Medpace position peaked at $37.7M in Q1 2024.
- 729 funds tracked by Wall St. Rank held Medpace as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.